Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -58.72% is 28% below its 5-year average of -45.92%, near the low end of its 5-year range (-58.72%–-17.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.90% below its 12-month average of -55.45%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -58.72%.
RETURN ON INVESTED CAPITAL (ROIC)
-58.72%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-55.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-48.50%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-45.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-41.97%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.90%
CURRENT VS 3Y AVG
-21.07%
CURRENT VS 5Y AVG
-27.87%
CURRENT VS 10Y AVG
-39.92%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-64.73%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$271.00M
Return on Invested Capital (ROIC)
-58.72%
TTM Avg
-55.45%
3Y Avg
-48.50%
5Y Avg
-45.92%
Market Cap
$271.06M
Return on Invested Capital (ROIC)
-31.62%
TTM Avg
-73.81%
3Y Avg
-69.44%
5Y Avg
-42.80%
Market Cap
$271.89M
Return on Invested Capital (ROIC)
-48.92%
TTM Avg
-66.11%
3Y Avg
-56.53%
5Y Avg
-47.58%
Market Cap
$270.20M
Return on Invested Capital (ROIC)
-37.64%
TTM Avg
-32.22%
3Y Avg
-29.09%
5Y Avg
-21.19%
Market Cap
$270.31M
Return on Invested Capital (ROIC)
-74.73%
TTM Avg
-25.64%
3Y Avg
-13.00%
5Y Avg
-6.89%
Market Cap
$269.70M
Return on Invested Capital (ROIC)
-59.50%
TTM Avg
-188.11%
3Y Avg
-308.62%
5Y Avg
-250.56%
Market Cap
$272.46M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.63M
Return on Invested Capital (ROIC)
-42.92%
TTM Avg
-30.10%
3Y Avg
-80.25%
5Y Avg
-64.52%
Market Cap
$264.94M
Return on Invested Capital (ROIC)
-170.19%
TTM Avg
-56.97%
3Y Avg
-50.85%
5Y Avg
-45.83%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $271.00M | -58.72% | -55.45% | -48.50% | -45.92% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $271.06M | -31.62% | -73.81% | -69.44% | -42.80% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.89M | -48.92% | -66.11% | -56.53% | -47.58% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.20M | -37.64% | -32.22% | -29.09% | -21.19% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | -74.73% | -25.64% | -13.00% | -6.89% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.70M | -59.50% | -188.11% | -308.62% | -250.56% |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.46M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.63M | -42.92% | -30.10% | -80.25% | -64.52% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | -170.19% | -56.97% | -50.85% | -45.83% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -28.96% | -103.16% | -110.30% | -171.09% |
ROIC
-58.7%
ROE
-82.1%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -58.72% |
| 2026-03-31 | -54.84% |
| 2025-12-31 | -52.22% |
| 2025-09-30 | -55.37% |
| 2025-06-30 | -56.09% |
| 2025-03-31 | -53.17% |
| 2024-12-31 | -52.29% |
| 2024-09-30 | -42.33% |
| 2024-06-30 | -39.57% |
| 2024-03-31 | -40.61% |
| 2023-12-31 | -40.25% |
| 2023-09-30 | -40.68% |
| 2023-06-30 | -44.33% |
| 2023-03-31 | -44.70% |
| 2022-12-31 | -52.14% |
| 2022-09-30 | -48.55% |
| 2022-06-30 | -39.35% |
| 2022-03-31 | -31.42% |
| 2021-12-31 | -25.83% |
| 2021-09-30 | -20.28% |
| 2021-06-30 | -17.35% |
| 2021-03-31 | -14.69% |
| 2020-12-31 | -23.71% |
| 2020-09-30 | -21.63% |
| 2020-06-30 | -19.55% |
| 2020-03-31 | -38.65% |
| 2019-12-31 | -36.70% |
| 2019-09-30 | -28.04% |
| 2019-06-30 | -43.93% |
| 2019-03-31 | -37.33% |
| 2018-12-31 | -35.65% |
| 2018-09-30 | -31.21% |
| 2018-06-30 | -81.64% |
| 2018-03-31 | -56.63% |
| 2017-12-31 | -44.70% |
| 2017-09-30 | -59.62% |
| 2017-06-30 | -54.00% |
| 2017-03-31 | -44.73% |
| 2016-12-31 | -36.30% |
| 2016-09-30 | -73.22% |
| 2016-06-30 | -68.27% |
| 2016-03-31 | -54.02% |
| 2015-12-31 | -44.76% |
| 2015-09-30 | -38.14% |
| 2015-06-30 | -34.23% |
| 2015-03-31 | -61.19% |
| 2014-12-31 | -51.70% |
| 2014-09-30 | -54.60% |
| 2014-06-30 | -56.88% |
| 2014-03-31 | -45.68% |
| 2013-12-31 | -33.53% |
| 2013-09-30 | -88.51% |
| 2013-06-30 | -565.69% |
